ReviewAmerican journal of translational research2024
Therapeutic effectiveness and safety profile of lanthanum carbonate in conjunction with calcium carbonate for managing hyperphosphatemia in hemodialysis patients: a meta-analysis of randomized controlled trials.
Review in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo comprehensively investigate the efficacy and safety of lanthanum carbonate in conjugation with calcium carbonate combination in hemodialysis patients with hyperphosphatemia via a meta-analysis of randomized controlled trials (RCTs).
methodWe conducted a literature search in databases of PubMed, Embase, and Web of Science for RCTs investigating the effect of lanthanum carbonate in combination with calcium carbonate for treating hyperphosphatemia in hemodialysis patients. The search covered all studies from the inception of the database until October 2023. Data extraction and quality assessment were performed on eligible studies, followed by a meta-analysis using RevMan5.3 software.
resultsTen studies fulfilling the inclusion criteria were included, with a sample size of 475 patients (256 in the experimental group who received lanthanum carbonate and calcium carbonate; 219 in the control group who received calcium carbonate alone). The experimental group showed a significantly higher clinical response rate compared to the control group [Relative Risk (RR) = 1.21, 95% CI = (1.12, 1.30), P < 0.01]. Moreover, the serum phosphorus levels [MD = -0.34, 95% CI = (-0.39, -0.29), P < 0.01], serum calcium levels [MD = -0.09, 95% CI = (-0.14, -0.05), P < 0.01], serum intact parathyroid hormone (iPTH) levels [MD = -35.05, 95% CI = (-45.31, -24.796), P < 0.01], and the incidence of adverse reactions [RR = 1.22, 95% CI = (1.08, 1.39), P < 0.01] were all lower in the experimental group compared to those in the control group. The funnel plot exhibited symmetrical distribution, and Egger's and Begg's tests did not reveal any evidence of significant publication bias (all P > 0.05).
conclusionsThe combined use of lanthanum carbonate and calcium carbonate demonstrates a superior clinical efficacy in the management of hyperphosphatemia in hemodialysis patients, as compared to the use of calcium carbonate as a standalone treatment. To corroborate these findings, it is essential to conduct additional multi-center, RCTs with substantial sample sizes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.